LENZ Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
LENZ$4.29+22.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except for shares and par value)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $20,158 | $35,140 |
| Marketable securities | 188,872 | 30,654 |
| Prepaid expenses and other current assets | 2,773 | 1,450 |
| Restricted cash | 114 | — |
| Total current assets | 211,917 | 67,244 |
| Property and equipment, net | 651 | 54 |
| Operating lease right-of-use asset | 1,338 | 318 |
| Deferred offering costs | — | 2,739 |
| Other assets | 1,398 | 21 |
| Total assets | $215,304 | $70,376 |
| Liabilities, convertible preferred and common stock and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $4,257 | $5,711 |
| Accrued liabilities | 6,149 | 12,803 |
| Total current liabilities | 10,406 | 18,514 |
| Operating lease liability, net | 814 | 192 |
| Other noncurrent liabilities | — | 121 |
| Preferred stock warrants liability | — | 871 |
| Total liabilities | 11,220 | 19,698 |
| Commitments and contingencies (Note 7) | ||
| Convertible preferred and common stock: | ||
| Series A convertible preferred stock, par value of $0.001 per share; no shares and 22,791,777 shares authorized at December 31, 2024 and 2023, respectively; no shares and 21,977,282 shares issued and outstanding at December 31, 2024 and 2023, respectively | — | 44,621 |
| Series A-1 convertible preferred stock, par value of $0.001 per share; no shares and 2,950,548 shares authorized at December 31, 2024 and 2023, respectively; no shares and 2,950,548 issued and outstanding at December 31, 2024 and 2023, respectively | — | 9,893 |
| Series B convertible preferred stock, par value of $0.001 per share; no shares and 28,019,181 shares authorized at December 31, 2024 and 2023, respectively; no shares and 28,019,181 issued and outstanding at December 31, 2024 and 2023, respectively | — | 82,976 |
| Class B convertible common stock, par value of $0.001 per share; no shares and 2,744,184 shares authorized at December 31, 2024 and 2023, respectively; no shares and 2,744,184 shares issued and outstanding at December 31, 2024 and 2023, respectively | — | 5,900 |
| Total convertible preferred and common stock | — | 143,390 |
| Stockholders' equity (deficit) (1): | ||
| Common stock, par value of $0.00001 per share; 300,000,000 and 16,017,929 shares authorized at December 31, 2024 and 2023, respectively; 27,531,490 and 2,004,783 shares issued at December 31, 2024 and 2023, respectively; and 27,518,439 and 1,969,360 shares outstanding at December 31, 2024 and 2023, respectively | 1 | 10 |
| Additional paid-in capital | 348,901 | 2,517 |
|---|---|---|
| Accumulated deficit | (145,014) | (95,245) |
| Accumulated other comprehensive income | 196 | 6 |
| Total stockholders’ equity (deficit) | 204,084 | (92,712) |
| Total liabilities, convertible preferred and common stock and stockholders’ equity (deficit) | $215,304 | $70,376 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.